OneSource Specialty Pharma Limited is engaged in the research, development, manufacturing, and commercialization of biological drug products, including injectables, with a strong focus on CDMO services.

Recently, the company proposed acquisitions to enhance its global footprint, aiming for a substantial capacity increase, indicating a strong growth trajectory and strategic positioning within the pharma sector.

For Q2FY26, OneSource reported a 12% YoY revenue growth and a substantial 37% increase in EBITDA, marking a significant profitability boost compared to the prior year.

The company is accelerating its phase 2 capacity expansion, driven by strong demand forecasts and multiple customer engagements across regions such as Canada, MENA, Brazil, and India.

OneSource is set to benefit from industry tailwinds, particularly from biosimilar approval pathway simplifications and increased interest from innovators and biosimilar firms for integrated manufacturing solutions.